View Post

FDA Fast Tracks Emiltatug Ledadotin in Advanced/Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Jordyn Sava From: targetedonc.com The FDA has granted a new fast track designation to emiltatug ledadotin for the treatment of advanced or metastatic breast cancer, specifically targeting patients with HER2-low or HER2-negative disease, including TNBC.1 This designation applies to patients who have previously received a topoisomerase-1 inhibitor antibody-drug conjugate (ADC). Additionally, hormone-receptor positive patients must have either received prior …